Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
Summary
Allogene plans to deploy miCAR with other technologies to develop next-generation strategies for immune evasion and other advances in allogeneic CAR T therapy.We believe that Antion has one of the few technology options capable of delivering multiplex gene silencing with a high degree of specificity and potency, said , M.D., Executive Vice President of Research and Development and Chief Medical Officer. Allogene will also take a seat on Antions Board of Directors.This collaboration represents an exciting validation of the power and flexibility of our miCAR platform, said , M.D., Chief Executive Officer. Antions proprietary Tunable Expression Modulators (TEM) and miCAR technologies allow efficient, simultaneous multi-gene silencing and gene addition in a single step, enabling the creation of multimodal treatments that have the ability to substantially enhance clinical safety and efficacy. Antions pipeline is focused on curing challenging cancer and immunotherapy indications with simple, easy to administer cell therapies.For more information please visit: https://antion.ch/About Allogene Therapeutics , with headquarters in , is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.